Delcath Systems, Inc. (DCTH)
| Market Cap | 343.88M -15.4% |
| Revenue (ttm) | 79.60M +251.5% |
| Net Income | 1.20M |
| EPS | 0.03 |
| Shares Out | 34.70M |
| PE Ratio | 287.20 |
| Forward PE | 67.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 401,041 |
| Open | 9.84 |
| Previous Close | 9.91 |
| Day's Range | 9.75 - 9.97 |
| 52-Week Range | 8.12 - 18.23 |
| Beta | 0.39 |
| Analysts | Strong Buy |
| Price Target | 23.00 (+132.09%) |
| Earnings Date | Mar 5, 2026 |
About DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in... [Read more]
Financial Performance
In 2024, Delcath Systems's revenue was $37.21 million, an increase of 1701.69% compared to the previous year's $2.07 million. Losses were -$26.39 million, -44.66% less than in 2023.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price target is $23.0, which is an increase of 132.09% from the latest price.
News
Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...
Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade
Delcath Systems is upgraded from Hold to Buy as sales stabilize and insider confidence grows. DCTH expects to hit the upper end of 2025 guidance at $85M, signaling operational stabilization after earl...
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancer...
Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancer...
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath”) an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today a...
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancer...
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancer...
Delcath Systems to Participate in Upcoming Investor Conferences
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...
Delcath: Temporary Headwinds Are No Cause For Concern
Delcath's third quarter was weak due to seasonality and pricing headwinds, but data suggests these are temporary challenges. Delcath continues to expand its treatment sites and sales force, which shou...
Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript
Delcath Systems, Inc. ( DCTH) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - C...
Delcath Systems Reports Third Quarter 2025 Results and Business Highlights
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancer...
Delcath Systems to Host Third Quarter 2025 Earnings Call
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it ...
Delcath Systems, Inc. (DCTH) Discusses CHOPIN Trial Results and Preliminary Q3 Financials Transcript
Delcath Systems, Inc. (NASDAQ:DCTH) Discusses CHOPIN Trial Results and Preliminary Q3 Financials October 20, 2025 8:45 AM EDT Company Participants David Hoffman - General Counsel, Corporate Secretary...
Delcath: Large Upside With Limited Downside Risk
Delcath offers a liver-directed chemotherapy system, which is currently used to treat metastatic uveal melanoma patients. Delcath is facing pricing pressure and slow hospital onboarding at the moment,...
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary...
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the result...
Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the accept...
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the f...
Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript
Delcath Systems, Inc. (NASDAQ:DCTH) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Ger...
Delcath Systems Reports Second Quarter 2025 Results and Business Highlights
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancer...
Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...
Delcath Systems to Host Second Quarter 2025 Earnings Call
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it ...
Delcath Systems: Growing Fast, But Business Model Is Fragile
Delcath's HEPZATO shows rapid sales growth and high pricing, but its efficacy is only moderately better than alternatives and not curative. The addressable market is small, treatment is complex, and f...